Tilray Brands (TLRY) Change in Receivables (2017 - 2026)
Tilray Brands' (TLRY) quarterly Change in Receivables came in at $69.5 million in Q2 2026, up 283.73% YoY from $18.1 million in Q2 2025, and up 647.66% on a QoQ basis from $9.3 million in Q1 2026.
Tilray Brands (TLRY) Change in Receivables (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Change in Receivables data on file, last reported at $69.5 million in Q2 2026.
- Quarterly Change in Receivables rose 283.73% year-over-year to $69.5 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $66.4 million (up 273.14% YoY) and the FY2026 annual result came in at $66.4 million, up 273.14% from the prior year.
- Change in Receivables rose to $69.5 million in Q2 2026, from $9.3 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $69.5 million in Q2 2026 to a low of -$14.4 million in Q3 2025.
- A 5-year average of $5.3 million and a median of $3.1 million in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2025 — Change in Receivables sank 789.18% — and 2026, when it soared 283.73%.
- Tracing TLRY's Change in Receivables over 5 years: stood at -$9.8 million in 2022, then soared by 187.31% to $8.5 million in 2023, then retreated by 21.26% to $6.7 million in 2024, then plunged by 70.25% to $2.0 million in 2025, then surged by 3383.97% to $69.5 million in 2026.
- The last three Change in Receivables figures came in at $69.5 million (Q2 2026), $9.3 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn | 69.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 69.54 Mn |
| May 31, 2026 | 69.54 Mn |
| Feb 28, 2026 | 9.30 Mn |
| Feb 28, 2026 | 9.30 Mn |
| Nov 30, 2025 | 2.00 Mn |
| Nov 30, 2025 | 2.00 Mn |
| Aug 31, 2025 | -14.41 Mn |
| Aug 31, 2025 | -14.41 Mn |
| May 31, 2025 | 18.12 Mn |
| May 31, 2025 | 18.12 Mn |
| Feb 28, 2025 | -9.37 Mn |
| Feb 28, 2025 | -9.37 Mn |
| Nov 30, 2024 | 6.71 Mn |
| Nov 30, 2024 | 6.71 Mn |
| Aug 31, 2024 | 2.34 Mn |
| Aug 31, 2024 | 2.34 Mn |
| May 31, 2024 | 12.15 Mn |
| May 31, 2024 | 12.15 Mn |
| Feb 29, 2024 | -1.05 Mn |
| Feb 29, 2024 | -1.05 Mn |